Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can interferon keep melanoma from coming back after surgery?

NCT ID NCT07671495

Disease control Sponsor: MIPO Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This completed phase 2 trial tested whether adding alpha interferon to standard surgery helps prevent skin melanoma from returning. 278 participants with stage I-IV melanoma were assigned to one of six groups, including surgery alone, low or high dose interferon, chemotherapy, or radiation. The study measured how long people lived without their cancer coming back and overall survival at 5 years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
alpha interferon
What this could lead to
If successful, this could point toward a standard way to use alpha interferon after melanoma surgery to reduce the chance of the cancer coming back.
What could go wrong
This is a completed phase 2 trial, so results are not yet confirmed in larger studies. Interferon can cause side effects like flu-like symptoms and fatigue, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

278 people

The number who actually took part.

Started

Jan 2014

Finished

Dec 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Histologically confirmed diagnosis of skin melanoma (stages I-IV according to TNM classification) * Underwent complete surgical resection of primary tumor with negative margins * Age 18 years or older * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Life expectancy of at least 6 months * Adequate bone marrow function: absolute neutrophil count ≥ 1.5 × 10⁹/L, platelet count ≥ 100 × 10⁹/L, hemoglobin ≥ 90 g/L * Adequate hepatic function: bilirubin ≤ 1.5 × upper limit of normal (ULN), transaminases ≤ 2.5 × ULN * Adequate renal function: creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min * Willing and able to provide written informed consent * Willing to comply with study procedures and follow-up schedule Exclusion Criteria: * • Presence of distant metastases at the time of diagnosis (except for stage IV patients included per protocol) * Prior immunotherapy, chemotherapy, or radiotherapy for melanoma * History of other malignant neoplasms within the past 5 years (except non-melanoma skin cancer or carcinoma in situ of the cervix) * Severe or uncontrolled organ dysfunction (cardiac, hepatic, renal, pulmonary) * Active infection requiring systemic therapy * Known hypersensitivity to interferon-alpha or any study medications * Known hypersensitivity to dacarbazine, cisplatin, or any excipients * Pregnancy or breastfeeding * Psychiatric or cognitive impairment that would interfere with study participation * Participation in another interventional clinical trial within 30 days prior to enrollment * Any condition that, in the investigator's opinion, would compromise participant safety or interfere with study objectives

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melanoma stage I are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melanoma stage I Melanoma stage III Melanoma, stage II Skin melanoma

More trials for these conditions

Other studies related to the condition(s) this trial covers.